Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.

<h4>Background</h4>There is an urgent need for an effective tuberculosis (TB) vaccine. Heterologous prime-boost regimens induce potent cellular immunity. MVA85A is a candidate TB vaccine. This phase I clinical trial was designed to evaluate whether alternating aerosol and intradermal vac...

Full description

Bibliographic Details
Main Authors: Zita-Rose Manjaly Thomas, Iman Satti, Julia L Marshall, Stephanie A Harris, Raquel Lopez Ramon, Ali Hamidi, Alice Minhinnick, Michael Riste, Lisa Stockdale, Alison M Lawrie, Samantha Vermaak, Morven Wilkie, Henry Bettinson, Helen McShane
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-04-01
Series:PLoS Medicine
Online Access:https://doi.org/10.1371/journal.pmed.1002790

Internet

https://doi.org/10.1371/journal.pmed.1002790

Similar Items